Paradigm Biopharmaceuticals (ASX:PAR) Common Stock: A$260.88 Mil (As of Dec. 2025)


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
26 GF Score
Price A$0.17
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals Common Stock?

Paradigm Biopharmaceuticals ASX:PAR -5.56% 26 Common Stock is A$260.88 Mil as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 26/100. The stock has 5 warning signs investors should review.

Paradigm Biopharmaceuticals's quarterly common stock declined from Dec. 2024 (A$253.24 Mil) to Jun. 2025 (A$253.23 Mil) but then increased from Jun. 2025 (A$253.23 Mil) to Dec. 2025 (A$260.88 Mil).

Paradigm Biopharmaceuticals's annual common stock increased from Jun. 2023 (A$209.83 Mil) to Jun. 2024 (A$238.11 Mil) and increased from Jun. 2024 (A$238.11 Mil) to Jun. 2025 (A$253.23 Mil).

Paradigm Biopharmaceuticals Common Stock Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals Common Stock Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 146.99 147.20 209.83 238.11 253.23

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 238.11 238.11 253.24 253.23 260.88
ASX:PAR
26GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$260.88 Mil mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a Common Stock of A$260.88 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Paradigm Biopharmaceuticals and its competitors.
Is Paradigm Biopharmaceuticals' Common Stock too high?
Paradigm Biopharmaceuticals' current Common Stock is A$260.88 Mil. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Common Stock compare to VRTX and REGN?
Paradigm Biopharmaceuticals' Common Stock of A$260.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current Common Stock is A$260.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Common Stock of A$260.88 Mil. The current Common Stock is A$260.88 Mil. Paradigm Biopharmaceuticals' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Common Stock is A$260.88 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
26GF Score

Get the complete analysis for ASX:PAR

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.17
Price